Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2021 | $10.00 | Buy | Truist Securities |
| 10/6/2021 | $12.00 | Buy | Needham |
| 9/29/2021 | $13.00 | Buy | Maxim Group |
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i
SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
SC 13D/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. "Clarus delivered solid growth in net revenu
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes. Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)
Truist Securities initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $10.00
Needham initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of Clarus Therapeutics with a rating of Buy and set a new price target of $13.00
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs
Gainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares surged 103.9% to settle at $5.30 on Tuesday. Shares are in low-float territory; the issue has about 15 million shares in its float. NewAge, Inc. (NASDAQ:NBEV) shares jumped 74.2% to close at $0.3632 on Tuesday. IN8bio, Inc. (NASDAQ:INAB) surged 39.4% to settle at $2.76 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. TMC the metals company Inc. (NASDAQ:TMC) jumped 33.3% to close at $1.12. The company recently posted a quarterly loss of $0.05 per share. TDH Holdings, Inc. (NASDAQ:P
Gainers NewAge, Inc. (NASDAQ:NBEV) rose 54.4% to $0.3220. IN8bio, Inc. (NASDAQ:INAB) jumped 46% to $2.89 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. Mobile Global Esports Inc. (NASDAQ:MGAM) shares jumped 45% to $3.7705. Shares are in low-float territory; the issue has about 15 million shares in its float. Forge Global Holdings, Inc. (NYSE:FRGE) gained 26.7% to $4.37. Virax Biolabs Group Limited (NASDAQ:VRAX) gained 20% to $3.94. American Outdoor Brands, Inc. (NASDAQ:AOUT) surged 18% to $9.17 after B. Riley upgraded the stock from
On Tuesday, 250 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Toyota Motor (NYSE:TM) was the biggest company on a market cap basis to set a new 52-week low. SciSparc (NASDAQ:SPRC) was the smallest firm by market cap to set a new 52-week low. Rubicon Technology (NASDAQ:RBCN)'s stock traded down the lowest, falling 74.66% to reach a new 52-week low. Grupo Aval Acciones (NYSE:AVAL)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low. On Tuesday, the following stocks set new 52-week lows: Toyota Motor (NYSE:TM) stock drifted down 0.45% on Tuesday morning to hit a new 52-week low of $150.59. Comcast (NASDA